DOCSLIB.ORG

SCIENTIFIC REPORT 2017 Cruk.Org SCIENTIFIC COVER IMAGE Mitochondria, the Powerhouses of the Cell, Are Required for Cancer Cell Death

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SCIENTIFIC REPORT 2017 Cruk.Org SCIENTIFIC COVER IMAGE Mitochondria, the Powerhouses of the Cell, Are Required for Cancer Cell Death SCIENTIFIC REPORT 2017 cruk.org SCIENTIFIC COVER IMAGE Mitochondria, the powerhouses of the cell, are required for cancer cell death. This image shows mitochondrial shape REPORT changes during cancer cell death, where each colour represents mitochondrial shape at a specific time point during cell death. Image supplied by Joel Riley, a post-doc in Stephen Tait’s group. 2017 BEATSON INSTITUTE CONTENTS SECTION 1 Shehab Ismail 52 DIRECTOR'S INTRODUCTION 04 Structural Biology of Cilia INSTITUTE OF CANCER SCIENCES 06 Laura Machesky 54 INTRODUCTION Migration, Invasion and Metastasis RESEARCH HIGHLIGHTS 08 Jim Norman 56 GABRIELA KALNA OBITUARY 11 Integrin Cell Biology TESSA HOLYOAKE OBITUARY 12 Michael Olson 58 BACKGROUND 13 Molecular Cell Biology Owen Sansom 60 CANCER RESEARCH UK BEATSON INSTITUTE Colorectal Cancer and Wnt Signalling Sara Zanivan 62 CANCER GROWTH AND METABOLISM Tumour Microenvironment and Proteomics Imran Ahmad 16 Models of Advanced Prostate Cancer DRUG DISCOVERY Peter D. Adams 18 Justin Bower & Heather McKinnon 66 Epigenetics of Cancer and Ageing Drug Discovery Unit Eyal Gottlieb 20 Tumour Metabolism ADVANCED TECHNOLOGIES Danny Huang 22 Leo Carlin 70 Ubiquitin Signalling Beatson Advanced Imaging Resource (BAIR) Jurre Kamphorst 24 Bioinformatics and Computational Biology 72 Cancer Metabolomics Sara Zanivan 73 Hing Leung 26 Proteomics Prostate Cancer Biology Emma Shanks 74 David Lewis 28 Functional Screening Molecular Imaging Gillian Mackay 76 Daniel J. Murphy 30 Metabolomics Oncogene-Induced Vulnerabilities Jennifer Morton 78 Kevin Ryan 32 Preclinical Precision Pancreas Tumour Cell Death Karen Blyth 80 Stephen Tait 34 Transgenic Models of Cancer Mitochondria and Cell Death Douglas Strathdee 82 Saverio Tardito 36 Transgenic Technology Oncometabolism David Lewis 84 Alexei Vazquez 38 Translational Molecular Imaging Mathematical Models of Metabolism SECTION 3 CANCER METASTASIS AND RECURRENCE Cancer Research UK Beatson Institute building RESEARCH FACILITIES 88 Tom Bird 42 PUBLICATIONS 92 Liver Disease and Regeneration CONFERENCES AND WORKSHOPS 112 David Bryant 44 SEMINARS 114 Molecular Control of Epithelial Polarity STUDENTSHIPS AND POSTDOCTORAL 116 Leo Carlin 46 FELLOWSHIPS Leukocyte Dynamics OPERATIONAL SERVICES 118 Seth Coffelt 48 THANKS FOR SUPPORTING US 120 Immune Cells and Metastasis PATRONS AND BOARD OF DIRECTORS 122 CONTACT DETAILS 123 Robert Insall 50 Cell Migration and Chemotaxis 2 SCIENTIFIC REPORT 2017 CANCER RESEARCH UK BEATSON INSTITUTE 3 DIRECTOR’S INTRODUCTION Researchers Drs Saadia Karim and David Vincent receive recognition for their research engagement activities In August of this year, Professor Owen Sansom was appointed as the next Director of the Cancer Research UK Beatson Institute. As its newest Director, Owen here sets out his vision for the Institute's strategy over the next five to ten years, along with some of the research highlights there were during 2017. Vision and strategy including for a number of senior clinicians in the Director of the Cancer Research Over the past ten years, the Beatson Institute has areas of particular clinical interest in Glasgow, UK Beatson Institute built an excellent reputation for basic cancer such as colorectal cancer and hepatocellular research, including world-class metabolism carcinoma. Professor studies and renowned in vivo modelling of Owen Sansom tumour growth and metastasis. This is Highlights FRSE, FMedSci something that current and former members of This has been our most successful year in the Institute can be very proud of. My goal for winning external grant funding and finding ways and now heads up both her research group and Martin Drysdale resigned as Director of the Drug the future is for this discovery work to continue to expand our research base, including the Proteomics team. We also held a number of Discovery Unit (DDU) in July to take up a apace but for it to also be applied to preclinical functional imaging, precision medicine and advisory mid-term reviews, for junior group prestigious role at the Broad Institute in the US, and clinical studies. This will include working informatics. leaders Dr Alexei Vazquez and Dr David Bryant and in the interim period our respective heads of with the well-established clinical pipeline in and for clinician scientist Dr Tom Bird. We are very chemistry and biology, Justin Bower and Heather Glasgow, exemplified by initiatives such as Two large initiatives, which researchers at the grateful to all of the external reviewers who McKinnon, have been acting as DDU leads. They PRECISION-Panc, which began this year. To do Institute are participating in, began this year. The participated in these important meetings. have recently been appointed as joint heads of this, we will work closely with colleagues in the Grand Challenge team (led by Josephine Bunch, the DDU, and we will work with them very closely wider Glasgow Cancer Centre, particularly National Physics Laboratory) is focusing on I was pleased by the progress of some of our in the coming years to develop exciting new clinical academics and clinicians focused on using state-of-the-art mass spectrometry intermediate clinicians this year - Colin Steele (a targets for cancer treatment. Mike Olson will also the treatment of cancer patients. imaging to map metabolism in vivo, something former clinical research fellow in my group) was be leaving the Institute in April 2018 to lead a that aligns very closely with previous work at the awarded an NHS Education Scotland/CSO department in Ryerson University (Toronto), As a core-funded Institute, I believe we also Institute. Meanwhile, PRECISION-Panc (led by Postdoctoral Clinical Lectureship, while Nigel bringing cancer and physical sciences together need to continue to do high-risk/high-gain Andrew Biankin, Owen Sansom and Jeff Evans) Jamieson won a CRUK Intermediate Clinical after winning a highly competitive Canada projects, and an important component of this aims to utilise functional stratified medicine Fellowship. I was also delighted to be elected a Research Chair. will be the advanced technologies established approaches to deliver new treatment options for Fellow of the Academy of Medical Sciences. In both within the Institute and the University of pancreatic cancer. Much of the preclinical work addition, two of our researchers, Drs Saadia In memory Glasgow, which underpin much of what we do. will be done within the Institute, in particular by Karim and David Vincent, were recognised with The year ended on an incredibly sad note with Our research themes will remain broadly the Dr Jennifer Morton, who now leads the CRUK Flame of Hope Special Commendations the loss of two of our most outstanding and same (cancer growth and metabolism, and Preclinical Precision Pancreas Laboratory. for all of their research engagement activities unique contributors to cancer research in cancer metastasis and recurrence) but with a over the years, while Dr Emma Shanks was Glasgow - Professor Tessa Holyoake and Dr re-emphasis on: In addition, Pancreatic Cancer UK awarded us a awarded CRUK's Communications and Brand Gabriela Kalna. The very warm tributes paid to Future Leaders Academy, enabling us to appoint Ambassador Prize as an inspiring communicator them in this report (pages 11 and 12) demonstrate • Cancer vulnerabilities caused by their four PhD students, along with a fifth funded by of its research. how well regarded they were and how much aberrant metabolism; Pancreatic Cancer Scotland, to our graduate they will be missed as both friends and • Interplay between the tumour studentship programme, which this October Arrivals and departures colleagues. microenvironment, metastasis and saw its largest intake to date (23 students in In January, Dr David Lewis joined us from the recurrence; total). CRUK Cambridge Institute to establish preclinical • Biology of early disease, aimed at developing functional imaging at the Institute. In support of a ‘precision prevention’ approach. We continue to monitor the progress of our this, the Beatson Cancer Charity has provided research groups. Professors Robert Insall and generous funding (via the Glasgow Cancer Our aim will be to identify non-clinical and Laura Machesky's quinquennial reviews, held in Centre) that will allow the establishment of a clinical leads for each of our themes, and for May, were very positive, while Dr Sara Zanivan facility at Gartnavel for probe synthesis. This there to be a programme of recruitment, was promoted to Senior Staff Scientist in March includes the appointment of a senior chemist and a physicist to support the group. 4 SCIENTIFIC REPORT 2017 CANCER RESEARCH UK BEATSON INSTITUTE DIRECTOR’S INTRODUCTION 5 www.gla.ac.uk/researchinstitutes/cancersciences INSTITUTE OF CANCER SCIENCES INTRODUCTION This year, there were a number of highlights within the Institute of Cancer Sciences (ICS), University of Glasgow in line with its primary goal of delivering cutting-edge translational cancer research for patient benefit. Director of the Institute We saw the start of PRECISION-Panc, a dynamic Panc clinical development platform (Leads: Jeff of Cancer Sciences and coordinated research platform to define, Evans and Juan Valle, Manchester). The ultimate understand, test and implement stratified aim is to develop a multi-drug, multi-sub-study, Jeff Evans therapeutic strategies for pancreatic cancer biomarker-driven family of clinical trials that use FRCP Edin (PDAC). The initiative is centred on discovery state-of-the-art genomic profiling to match and preclinical and
Load more

Recommended publications
  • NCI RAS Initiative Update
    Ras Initiative Update Frank McCormick and Levi Garraway DEPARTMENT OF HEALTH AND HUMAN SERVICES • National Institutes of Health • National Cancer Institute The Frederick National Laboratory is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute RAS Initiative Accomplishments: Evaluating Ras dependency 2 SiREN assay for Ras dependency SiREN assay for Ras dependency 70% KD siEGFP 0-10% KD 50% KD 100% KD SiREN assay for Ras dependency RAS Initiative Accomplishments: Biophysical and structural analysis 7 Ras proteins 1 -166 167-185,6 Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Raf, PI 3’ kinase RalGDS, GAPs Palmitoyl Farnesyl Fully processed KRAS4b A. Gorfe, U-Texas Houston Engineering baculovirus for improved production of processed KRAS • recombineering used to insert FNTA/FNTB genes into the baculovirus genome • eliminated issues with coinfection of multiple viruses • maltose-binding protein (MBP) fusion for greater yield and solubility • Trichoplusia ni (Hi5) insect cells for increased yield Carissa Grose, Dom Esposito, Bill Gillette Processed KRAS4b characterization • Extensive protein characterization – Purified to homogeneity; yield >7mg/L – Intact mass – Predominantly monomeric – Secondary structure equivalent to non-processed KRAS4b KRAS4b- FME – Lower thermal stability Intact mass analysis Analytical ultracentrifugation Secondary structure by CD 2.14 S 25.7 kDa 10 Bill Gillette, Zhaojing Meng, Shelley Perkins,
    [Show full text]
  • Miriam Molina Arcas
    CV Miriam Molina Arcas Miriam Molina Arcas Principal Laboratory Research Scientist The Francis Crick Institute 1 Midland Road, NW1 1AT London +442037963313 [email protected] EDUCATION 1999-2005 PhD in Biomedicine, University of Barcelona, Spain Role of equilibrative nucleoside transporters in the sensitivity to antineoplasic drugs. Supervisors: Prof. Marçal Pastor-Anglada and Dr. F. Javier Casado 1994-1999 BSc Biochemistry, University of Barcelona, Spain RESEARCH AND PROFESSIONAL EXPERIENCE June 2016- present Senior Laboratory Research Scientist, Oncogene Biology Laboratory, The Francis Crick Institute. Prof. Julian Downward. Studied combination approaches that improve the efficacy of KRAS inhibitors and reduce resistance mechanisms. March 2015- May 2016 Postdoctoral Fellow, Lung Cancer Team, Institute of Cancer Research. Prof. Julian Downward. Designed and optimized a whole-genome shRNA screen to identify synthetic lethal interactions with MEK and IGF1R inhibitors. Sep 2008- Feb 2015 Postdoctoral Fellow, Signal Transduction Laboratory, Cancer Research UK- London Research Institute. Prof. Julian Downward Using RNA interfering and drug screens, identified new therapeutic strategies to treat tumours harbouring KRAS mutations 2006- Aug 2008 Postdoctoral Fellow, University of Barcelona, Spain Prof. Marçal Pastor-Anglada Studied the role of membrane transporters in nucleoside-derived drug response in cancer and HIV. TEACHING AND MENTORING EXPERIENCE 2018-2021 Honorary Research Associate in the School of Life & Medical Sciences, University College London, part of the Certificate in Core Teaching Practices. 2007-2008 Part-time lecturer of Biochemistry and Molecular Biology (University of Barcelona). 180h of theory and practical lessons. 2003-2005 Teaching assistant of Biochemistry and Molecular Biology (University of Barcelona). 60h of practical lessons. September 2019 Co-supervisor of MSc Experimental Pharmacology and Therapeutics Research of Pablo Romero Clavijo at the University College London.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • The Ubiquitin Proteasome System and Its Involvement in Cell Death Pathways
    Cell Death and Differentiation (2010) 17, 1–3 & 2010 Macmillan Publishers Limited All rights reserved 1350-9047/10 $32.00 www.nature.com/cdd Editorial The ubiquitin proteasome system and its involvement in cell death pathways F Bernassola1, A Ciechanover2 and G Melino1,3 Cell Death and Differentiation (2010) 17, 1–3; doi:10.1038/cdd.2009.189 Following the awarding of the 2004 Nobel Prize in Chemistry Inactivation of the proteasome following caspase-mediated to Aaron Ciechanover, Avram Hershko, and Irwin A Rose cleavage may disable the proteasome, interfering with its for the discovery of ubiquitin (Ub)-mediated degradation, role in the regulation of key cellular processes and thereby Cell Death and Differentiation has drawn the attention of facilitating induction of apoptosis. The noted recent develop- its readers to the Ub Proteasome System (UPS) and its ments show how understanding of these functions is just involvement in regulating cell death pathways.1–4 The current starting to emerge. For example, why does dIAP1 associate set of reviews is an update on this theme.5–16 with multiple E2s via its RING finger? Does dIAP1 also interact From previous review articles published in Cell Death and with the E3 – the F-box protein Morgue, which is a part of an Differentiation, it was apparent that the UPS has a major SCF E3 complex? Why does dIAP1, which is an E3, have to mechanistic role in regulating cell death via modification and interact with other ligases such as the N-end rule UBR1 and degradation of key regulatory proteins involved in
    [Show full text]
  • Unveiling New Disease, Pathway, and Gene Associations Via Multi-Scale Neural Networks
    Unveiling new disease, pathway, and gene associations via multi-scale neural networks Thomas Gaudelet 1, No¨elMalod-Dognin 2, Jon S´anchez-Valle 2, Vera Pancaldi 2,3,4, Alfonso Valencia 2,5,6 and NataˇsaPrˇzulj 2,5,∗ 1 Department of Computer Science, University College London, London, WC1E 6BT 2 Department of Life Sciences, Barcelona Supercomputing Center (BSC), Barcelona, 08034 Spain 3 Centre de Recherches en Canc´erologiede Toulouse (CRCT), UMR1037 Inserm, ERL5294 CNRS, 31037 Toulouse, France 4 University Paul Sabatier III, Toulouse, France 5 ICREA, Pg. Llu´ısCompanys 23, 08010 Barcelona, Spain 6 Coordination Node. Spanish National Bioinformatics Institute, ELIXIR-Spain (INB, ELIXIR-ES), Spain ∗ [email protected]. Abstract Diseases involve complex modifications to the cellular machinery. The gene expression profile of the affected cells contains characteristic patterns linked to a disease. Hence, new biological knowledge about a disease can be extracted from these profiles, improving our ability to diagnose and assess disease risks. This knowledge can be used for drug re-purposing, or by physicians to evaluate a patient's condition and co-morbidity risk. Here, we consider differential gene expressions obtained by microarray technology for patients diagnosed with various diseases. Based on these data and cellular multi-scale organization, we aim at uncovering disease{disease, disease{gene and disease{pathway associations. We propose a neural network with structure based on the multi- scale organization of proteins in a cell into biological pathways. We show that this model is able to correctly predict the diagnosis for the majority of patients. Through the analysis of the trained model, we predict disease{ disease, disease{pathway, and disease{gene associations and validate the predictions by comparisons to known interactions and literature search, proposing putative explanations for the predictions.
    [Show full text]
  • A Conversation with Karen Vousden
    A Conversation with Karen Vousden INTERVIEWER:JAN WITKOWSKI Executive Director, Banbury Center at Cold Spring Harbor Laboratory Karen Vousden is Director of the Cancer Research UK Beatson Institute. Jan Witkowski: Over the past few years, there’s been a tomography) imaging. It certainly is the case that many markedly increasing emphasis and interest in the metab- cancers have a high rate of glucose uptake, which is olism and biochemistry of cancers. It’s moving away what we measure when we do functional imaging, or a from just the genes and proteins. Am I right in thinking PET scan. that? However, over recent years our understanding of the Warburg effect has become more sophisticated, although Dr. Vousden: Yes, I think you’re absolutely right. we still don’t quite understand it. We know now that there There’s been a resurgence of interest in metabolism. In probably are changes in the metabolism of almost all the middle of the last century a lot of energy was spent on cancers. We’re interested in understanding that and then understanding metabolism and biochemists at this time asking, “Can we harness any of this information to were making huge progress. Many metabolic pathways develop new therapies?” were worked out in exquisite detail in the ’50s and the ’60s. Then came the oncogene revolution, and much of Jan Witkowski: Can you tell me a little about your the emphasis switched to understanding the regulation current work? of the cell cycle and signal transduction. At this point, metabolism was almost forgotten in cancer biology until Dr.
    [Show full text]
  • REPORTER No 6396 W E D N E S D Ay 23 S E P T E M B E R 2015 V O L C X Lv I N O 1
    CAMBRIDGE UNIVERSITY REPORTER NO 6396 W ED N E S D AY 23 S EPTEMBER 2015 V OL CXLV I N O 1 CONTENTS Notices Notices by Faculty Boards, etc. Calendar 2 Natural Sciences Tripos, Part II (Biological Notice of a Discussion on Tuesday, 13 October and Biomedical Sciences), 2015–16 11 2015 2 Natural Sciences Tripos, Part III (Experimental Preacher at Mere’s Commemoration in 2016 2 and Theoretical Physics) and Master of Nomination of the Proctors and Deputy Advanced Studies in Physics, 2015–16 12 Proctors for 2015–16 2 Form and conduct of examinations, 2016 Annual Reports 2 Asian and Middle Eastern Studies Tripos, Examination results statistics 2 Part II, 2016: correction 13 Vacancies, appointments, etc. Obituaries Electors to the Professorship of Comparative Obituary Notices 14 Philology 3 Graces Electors to the Professorship of Immunology 3 Grace submitted to the Regent House on Electors to the Sir Patrick Sheehy 23 September 2015 14 Professorship of International Relations 3 Acta Electors to the Professorship of Medieval History 4 Approval of Grace submitted to the Regent Electors to the William Wyse Professorship of House on 29 July 2015 14 Social Anthropology 4 Vacancies in the University 4 End of the Official Part of the ‘Reporter’ Elections, appointments, reappointment, and College Notices grants of title 5 Elections 15 Awards, etc. Vacancies 16 Scholarships and Prizes, etc. awarded 7 Other Notices 17 Events, courses, etc. Notice by the University Bellringer 17 Announcement of lectures, seminars, etc. 8 External Notices Notices by the General Board University of Oxford 17 Regulations for the University Library 9 The Cambridge Humanities Research Grants Scheme 9 Regulations for examinations Classical Tripos, Part II 10 Modern and Medieval Languages Tripos, Part IB 10 Bachelor of Theology for Ministry 10 PLISUB HED BY AUTHORITY 2 CAMBRIDGE UNIVERSITY REPORTER 23 September 2015 NOTICES Calendar 1 October, Thursday.
    [Show full text]
  • Fellows Opted out of the Mentoring Programme As of 21 July 2020 1 of 3 Professor Chris Abell FRS Fmedsci Professor Philip Jones
    Fellows opted out of the Mentoring programme as of 21 July 2020 Professor Chris Abell FRS FMedSci Professor Philip Jones FMedSci Professor David Adams FMedSci Professor Roger Jones FMedSci Professor Judith Allen FRSE FMedSci Professor Kamlesh Khunti FMedSci Professor Thomas Kirkwood CBE Professor Desmond Archer OBE FMedSci FMedSci Professor Louise Arseneault FMedSci Professor Robb Krumlauf FMedSci Professor Charalambos Kyriacou Professor Michael Arthur FMedSci FMedSci Professor Deborah Ashby OBE FMedSci Sir Peter Lachmann FRS FMedSci Professor Dame Frances Ashcroft DBE Professor Leon Lagnado FMedSci FRS FMedSci Professor Anthony Barrett FRS FMedSci Professor Ajit Lalvani FMedSci Professor Gillian Bates FRS FMedSci Professor Deborah Lawlor CBE FMedSci Professor Facundo Batista FMedSci Professor Joy Lawn FMedSci Professor Stephan Beck FMedSci Professor Susan Lea FMedSci Professor Jill Belch OBE FMedSci Professor Sir Robert Lechler PMedSci Professor Sir John Bell GBE FRS Dr Melanie Lee CBE FMedSci HonFREng FMedSci Professor Wendy Bickmore FRS FRSE Professor Andrew Lees FMedSci FMedSci Professor Sir Adrian Bird CBE FRS FRSE Professor Stafford Lightman FRS FMedSci FMedSci Professor Ewan Birney CBE FRS Professor Janet Lord FMedSci FMedSci Professor Dorothy Bishop FRS FBA Professor Thomas MacDonald FMedSci FMedSci Professor Rona MacKie CBE FRSE Professor Jane Blazeby FMedSci Sir Stephen Bloom FRS FMedSci Professor Giovanna Mallucci FMedSci Sir Tom Blundell FRS FMedSci Dr Fiona Marshall FMedSci Professor Dame Theresa Marteau DBE Professor Peter
    [Show full text]
  • 3718 Issue63july2010 1.Pdf
    Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 1 JULYJULLYY 2010 | ISSUEISSUE 63 GENETICSGENNETICSS SOCIETYSOCIEETY NENEWSEWS In this issue The Genetics Society NewsNewws is edited by U Genetics Society PresidentPresident Honoured Honoured ProfProf David Hosken and items ittems for future future issues can be sent to thee editor,editor, preferably preferably U Mouse Genetics Meeting by email to [email protected],D.J.Hosken@@exeter.ac.uk, or U SponsoredSponsored Meetings Meetings hardhard copy to Chair in Evolutionary Evoolutionary Biology, Biology, UniversityUniversity of Exeter,Exeter, Cornwall Cornnwall Campus, U The JBS Haldane LectureLecture Tremough,Tremough, Penryn, TR10 0 9EZ UK.UK. The U Schools Evolutionn ConferenceConference Newsletter is published twicet a year,year, with copy dates of 1st June andand 26th November.November. U TaxiTaxi Drivers The British YeastYeaste Group Group descend on Oxford Oxford for their 2010 meeting: m see the reportreport on page 35. 3 Image © Georgina McLoughlin Issue 63.qxd:Genetic Society News 1/10/10 14:41 Page 2 A WORD FROM THE EDITOR A word from the editor Welcome to issue 63. In this issue we announce a UK is recognised with the award of a CBE in the new Genetics Society Prize to Queen’s Birthday Honours, tells us about one of Welcome to my last issue as join the medals and lectures we her favourite papers by Susan Lindquist, the 2010 editor of the Genetics Society award. The JBS Haldane Mendel Lecturer. Somewhat unusually we have a News, after 3 years in the hot Lecture will be awarded couple of Taxi Drivers in this issue – Brian and seat and a total of 8 years on annually to recognise Deborah Charlesworth are not so happy about the committee it is time to excellence in communicating the way that the print media deals with some move on before I really outstay aspects of genetics research to scientific issues and Chris Ponting bemoans the my welcome! It has been a the public.
    [Show full text]
  • Drugging the Undruggable: Advances on RAS Targeting in Cancer
    G C A T T A C G G C A T genes Review Drugging the Undruggable: Advances on RAS Targeting in Cancer Miriam Molina-Arcas 1,*, Amit Samani 1,2,* and Julian Downward 1,3 1 Oncogene Biology Laboratory, Francis Crick Institute, London NW1 1AT, UK; [email protected] 2 Department of Medical Oncology, Imperial College Healthcare NHS Trust, London W2 1NY, UK 3 Lung Cancer Group, Institute of Cancer Research, London SW3 6JB, UK * Correspondence: [email protected] (M.M.-A.); [email protected] (A.S.) Abstract: Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for GTP, and the lack of suitable pockets for high-affinity small-molecule binding, precluded effective therapies despite decades of research. Recently, characterisation of the biochemical properties of KRAS-G12C along with discovery of its ‘switch-II pocket’ have allowed development of effective mutant-specific inhibitors. Currently seven KRAS-G12C inhibitors are in clinical trials and sotorasib has become the first one to be granted FDA approval. Here, we discuss historical efforts to target RAS directly and approaches to target RAS effector signalling, including combinations that overcome limitations of single-agent targeting. We also review pre-clinical and clinical evidence for the efficacy of KRAS-G12C inhibitor monotherapy followed by an illustration of combination therapies designed to overcome primary resistance and extend durability of response. Finally, we briefly discuss novel approaches to targeting non-G12C mutant isoforms.
    [Show full text]
  • Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017
    The Second RAS Initiative Symposium Sponsored by the National Cancer Institute Advanced Technology Research Facility, Frederick, MD December 6-8, 2017 December 6 8:00 am – 8:15 am Welcome from the NCI Director Norman Sharpless 8:15 am – 9:00 am Keynote Frank McCormick (RAS Initiative, University of California, San Francisco) 9:00 am – 9:30 am Organoids as Model Systems for Tumorigenesis Calvin Kuo (Stanford University) 9:30 am – 9:50 am Break 9:50 am – 12:10 pm Activated RAS and Oncogenesis - Chair: Jeff Settleman Douglas Lowy (National Cancer Institute) Christopher Counter (Duke University) Matthew Vander Heiden (Massachusetts Institute of Technology) Marie Evangelista (Genentech) Aaron Hobbs (Der Lab, University of North Carolina, Chapel Hill) 12:10 pm – 1:10 pm Lunch on your own 1:10 pm – 3:15 pm Poster Session #1 3:15 pm – 4:15 pm RAS Multimers at the Membrane - Chair: John Hancock Yao-Cheng Li (Wahl Lab, Salk Institute) Margie Sutton (Bast Lab, MD Anderson) Chiara Ambrogio (Jänne Lab, Dana Farber Cancer Institute) 4:15 pm – 5:30 pm RAS Membrane Modeling and Dynamics - Chair: Dwight Nissley Roland Winter (Technische Universität Dortmund) Fred Streitz (Lawrence Livermore National Laboratory) Chris Neale (Garcia Lab, Los Alamos National Laboratory) Walkersville Social Hall 79 West Frederick Street, Walkersville 6:15 – 7:00 pm Hors d’oeuvres, cash bar 7:00 pm Dinner December 7 8:00 am – 10:00 am Tumor Dynamics - Chair: Rosalie Sears Dafna Bar-Sagi (New York University) David Tuveson (Cold Spring Harbor Laboratory) Channing Der (University
    [Show full text]
  • Immune Homeostasis
    IMMUNE HOMEOSTASIS FUNDED PROJECTS FROM THE INNOVATION WORKSHOP 18-20 JULY 2017 AIMS THE SANDPIT PROCESS CAN BE BROKEN DOWN The immune system continues to intrigue and test us: as we get closer to finding ways of harnessing or modulating immune responses, new and unexpected consequences and INTO SEVERAL STAGES: challenges present themselves, often testing even our most fundamental understanding. Cancer Research UK and Arthritis Research UK came together to engage the research community to tackle the specific challenge of understanding how the immune system regulates itself under normal physiological conditions (immune homeostasis), how it is • Defining the scope of the challenge dysregulated in different diseases and how we can stimulate the immune response to prevent • Sharing understanding of the challenge and expertise brought to the sandpit by or treat disease (immunotherapy). participants We brought together researchers and clinicians in the fields of inflammatory disease, cancer, • Evolving common languages and terminologies amongst people from a diverse theoretical physics, computational medicine and other areas, whose expertise could be applied range of backgrounds and disciplines to the key questions concerning immune homeostasis. This workshop encouraged participants from a diverse range of backgrounds to melt barriers, develop a common language to promote • Breaking down preconceptions of researchers and stakeholders collaboration, and suggest new ways to harness the immune system to treat disease. • Taking part in break-out sessions focussed on challenges, using creative thinking techniques Director • Capturing outputs in the form of highly innovative feasibility study proposals The role of the Director was to work with the facilitators to lead the event and guide the process • A funding decision on those proposals at the sandpit, using “real time” peer-review.
    [Show full text]